These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12535263)

  • 1. Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient.
    Julin JE; van Burik JH; Krivit W; Webb C; Holman CJ; Clark HB; Balfour HH
    Transpl Infect Dis; 2002 Dec; 4(4):201-6. PubMed ID: 12535263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganciclovir-resistant cytomegalovirus encephalitis in a hematopoietic stem cell transplant recipient.
    Arslan F; Tabak F; Avşar E; Midilli K; Mert A; Ozaras R; Soysal T; Ozturk R; Ferhanoglu B
    J Neurovirol; 2010 Mar; 16(2):174-8. PubMed ID: 20345320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.
    Seo SK; Regan A; Cihlar T; Lin DC; Boulad F; George D; Prasad VK; Kiehn TE; Polsky B
    Clin Infect Dis; 2001 Nov; 33(9):e105-8. PubMed ID: 11577375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature.
    Baghban A; Malinis M
    J Neurol Sci; 2018 May; 388():28-36. PubMed ID: 29627026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
    Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
    Minces LR; Nguyen MH; Mitsani D; Shields RK; Kwak EJ; Silveira FP; Abdel-Massih R; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Toyoda Y; Clancy CJ
    Antimicrob Agents Chemother; 2014; 58(1):128-35. PubMed ID: 24145525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
    Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
    Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
    Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
    Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus encephalitis resistant to anti-cytomegalovirus therapy.
    Holida MD; Trigg ME; Rumelhart SL; Lee NF; Kook H; Peters C
    AIDS; 1995 May; 9(5):531-2. PubMed ID: 7639984
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of cytomegalovirus encephalitis in a patient with Hodgkin's disease in remission.
    Van Droogenbroeck J; De Ceuninck M; Snoeck HW; Schroyens W; Berneman Z
    Ann Hematol; 1998; 76(3-4):179-81. PubMed ID: 9619737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
    Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
    J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report.
    Nawashiro Y; Shiraki K; Yamamoto S; Takizawa K; Sasada Y; Suehiro M; Miura K; Hattori M; Daikoku T; Hisano M
    Transplant Proc; 2018 Dec; 50(10):3932-3936. PubMed ID: 30577289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
    Bacigalupo A; van Lint MT; Tedone E; Moro F; Sanna MA; Longren M; Trespi G; Frassoni F; Occhini D; Gualandi F
    Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C; LeBlanc MH; Boivin G
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis.
    Erice A; Borrell N; Li W; Miller WJ; Balfour HH
    J Infect Dis; 1998 Aug; 178(2):531-4. PubMed ID: 9697737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.
    Erice A; Gil-Roda C; Pérez JL; Balfour HH; Sannerud KJ; Hanson MN; Boivin G; Chou S
    J Infect Dis; 1997 May; 175(5):1087-92. PubMed ID: 9129070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
    Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
    Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.